Pfizer to expand Sayana Press contraceptive access to poor countries
Through this collaboration of organizations from the public and private sectors, Sayana Press will be sold for US $1 per dose to qualified purchasers, who can help enable
Through this collaboration of organizations from the public and private sectors, Sayana Press will be sold for US $1 per dose to qualified purchasers, who can help enable
JCRI composes part of USPI’s new 45,000 square-foot Canady Innovation Center (CIC), which houses a cross-functional team of global scientists, physicians, clinicians, healthcare professionals and engineers who collaborate
Neuren intends to submit applications to the US Food and Drug Administration (FDA) for both Orphan Drug and Breakthrough Therapy designation. Neuren expects to meet with the FDA
Capstone has been created through the integration of H.I.G. portfolio companies Integrity Nutraceuticals in Spring Hill, TN and Cornerstone Research & Development in Ogden, UT. Capstone will compete
Rociletinib is the Company’s novel, oral, targeted covalent (irreversible) mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in
The transaction was announced on September 29, 2014 and included upfront consideration of $600 million in cash and 3,209,971 shares of AMAG common stock, and additional contingent consideration
Irenas of the United States District Court for the District of New Jersey in the patent infringement lawsuit filed by Horizon against Watson Laboratories, Inc. for an Abbreviated
The NIH Proteus syndrome team is led by researchers who originally discovered the somatic single (point) mutation in the AKT 1 oncogene that causes Proteus syndrome. On that
In the initial phase of the clinical program scheduled to commence this month, eight (8) DKD patients will be enrolled. The objectives of this double blind, placebo controlled,
New, detailed results from part one of the Phase 2 portion of AbbVie’s Phase 2/3 open-label study, TURQUOISE-I, showed that patients co-infected with genotype 1 (GT1) HCV and